BioFuse Medical Technologies Appoints Dr. David Battleman as Chief Executive Officer

Proven healthcare executive and life sciences strategist joins to bring groundbreaking BioFuse Multi-Tissue Welder (MTW) technology to market

MELBOURNE, FL / ACCESSWIRE / March 26, 2024 / BioFuse Medical Technologies, a leading developer of radio frequency (RF) technology for surgical welding, today announced that David Battleman, MD, MBA, MSc, has been appointed as its President & Chief Executive Officer. Dr. Battleman brings a wealth of experience that strongly aligns with the company’s commitment to advancing healthcare through innovative surgical solutions and will lead BioFuse through the development and launch of the company’s RF surgical welding devices.

Dr. Battleman is the Principal & Founder of TrueNorth Lifesciences, a boutique life science strategic consulting and financial advisory firm, and has over 20+ years of working with highly innovative life science companies seeking to optimize and accelerate growth. Previously, Dr. Battleman served as a Senior Principal in the R&D and Commercial Strategy Practice of IMS Health Holdings, Inc. (now IQVIA; NYSE: IQV), a Fortune 500 company providing data and consulting services to the global pharmaceutical industry. Prior to joining IMS Health, he was a management consultant at Bain & Company and Sr. Director for Pfizer Pharmaceuticals. Dr. Battleman holds an MD from Weill Cornell Medical College, an MBA from the University of Pennsylvania’s Wharton School of Business, and an MSc from the Harvard School of Public Health.

Dr. David Battleman’s appointment as the CEO signifies a strategic advancement for BioFuse as the company positions itself at the forefront of surgical innovation. The BioFuse Board of Directors believes that Dr. Battleman’s extensive experience in healthcare & life science technology development & commercialization makes him an ideal leader to guide BioFuse through its next phase of growth. Commenting on BioFuse’s technology, Dr. Battleman stated, “I am excited to join BioFuse Medical Technologies at this critical juncture as the company advances its highly innovative Multi-Tissue Welding technology through late-stage development & commercialization. BioFuse MTW, as a multi-tissue welding device, has the potential to revolutionize a significant number of surgical procedures that require sutures or staples, improve patient recovery times, and address critical challenges in healthcare cost management.”

Dr. Joseph Stauffer, Chairman of BioFuse Medical Technologies, expressed his enthusiasm for the new leadership, saying, “We are confident that Dr. Battleman’s extensive background in healthcare, capital markets, and strategic leadership will further propel BioFuse towards achieving its mission. His appointment comes at a pivotal time for our company, and we look forward to the positive impact his expertise will have on advancing our innovative surgical solutions.”

About BioFuse Medical Technologies

BioFuse Medical Technologies, Inc. is a privately held medical device company headquartered in Melbourne, Florida. The company is dedicated to the development of the BioFuse Multi-Tissue Welder (MTW), an advanced electrosurgical platform designed to transform the current surgical landscape. The MTW technology is a breakthrough in multi-tissue welding, offering a proprietary high-frequency system that outperforms traditional sutures and staples, thereby enhancing patient outcomes and reducing healthcare costs. With a strong product pipeline, clear regulatory roadmap, and a market potential of $3 billion, BioFuse Medical Technologies is positioned to revolutionize and dominate the surgical suture, staple, and electrocautery vessel sealing markets in the United States and Europe.

Keep up with BioFuse’s latest advancements at and follow us on LinkedIn.

Investors interested in learning more about BioFuse Medical Technologies, Inc. and potential investment opportunities in the Company’s 506(c) offering can visit


David Battleman, MD, MSc, MBA
President & CEO
BioFuse Medical Technologies, Inc.
877-466-2434 (main office)


Doug Nissinoff
Investor Relations
Renegade BioConsulting, LLC
(954) 204-6745 (mobile)

SOURCE: BioFuse Medical Technologies, Inc.

View the original press release on

error: Content is protected !!